Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327698 | 0.81 | MAOB (0.51) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL6779534 | 0.79 | MAOB (0.65) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL6816962 | 0.79 | MAOB (0.69) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL5147803 | 0.79 | MAOB (0.57) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL277045 | 0.77 | GAA (0.47) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL7800195 | 0.77 | MAOB (0.58) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL103047 | 0.76 | MAOB (0.65) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL5078379 | 0.76 | MAOB (0.65) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL169289 | 0.76 | MAOB (0.65) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL4599839 | 0.76 | L3MBTL1 (0.66) | MAOBNR4A2NR4A1NR4A3PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133904-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8088798-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | Jensen Discovery, Inc. | 2012-01-03 | — | — | US | disclosed |
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2010-06-10 | — | — | US | disclosed |
| US-7687481-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | JENRIN DISCOVERY (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | JENRIN DISCOVERY (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | MAOB 3199/4885NR4A2 358/4885NR4A1 445/4885 |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | MAOB 3199/4885NR4A2 358/4885NR4A1 445/4885 |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | CNR2, CNR1, GPR119 | MAOB 2220/4885NR4A2 776/4885NR4A1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.